Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627476 | 0.93 | MEN1 (0.53) | HTR6MEN1MAPK1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1380515 | 0.86 | RAD52 (0.43) | MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL1381621 | 0.85 | SLC40A1 (0.52) | HTR6MEN1KMT2AGAA | |
| Trifluoroacetic Acid SCHEMBL1380631 | 0.80 | HTR6 (0.45) | HTR6MEN1KMT2A | |
| SCHEMBL7045097 | 0.80 | SLC40A1 (0.49) | HTR6 | |
| SCHEMBL3623702 | 0.80 | SLC40A1 (0.58) | HTR6ALDH1A1 | |
| SCHEMBL1379328 | 0.79 | TDP1 (0.50) | HTR6MEN1KMT2AALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL6047104 | 0.79 | SLC40A1 (0.47) | HTR6 | |
| Trifluoroacetic Acid SCHEMBL1380171 | 0.79 | L3MBTL1 (0.43) | HTR6 | |
| SCHEMBL1379816 | 0.78 | ALDH1A1 (0.37) | HTR6MEN1MAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4731114-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |